Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Authors
Keywords
-
Journal
Journal of Chemical Information and Modeling
Volume 62, Issue 2, Pages 412-422
Publisher
American Chemical Society (ACS)
Online
2022-01-06
DOI
10.1021/acs.jcim.1c01451
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
- (2022) Jiahui Chen et al. Journal of Chemical Information and Modeling
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries
- (2021) Rui Wang et al. GENOMICS
- The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
- (2021) Bryan E. Jones et al. Science Translational Medicine
- Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
- (2021) Jiahui Chen et al. JOURNAL OF MOLECULAR BIOLOGY
- Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
- (2021) Marta Alenquer et al. PLoS Pathogens
- Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
- (2021) Jinhui Dong et al. Nature Microbiology
- Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
- (2021) Rui Wang et al. Journal of Physical Chemistry Letters
- Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation
- (2021) Liping Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
- (2021) Li Zhang et al. Emerging Microbes & Infections
- Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
- (2021) Liane Dupont et al. Nature Microbiology
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- The race for coronavirus vaccines: a graphical guide
- (2020) Ewen Callaway NATURE
- A human monoclonal antibody blocking SARS-CoV-2 infection
- (2020) Chunyan Wang et al. Nature Communications
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
- (2020) Tyler N. Starr et al. CELL
- Mutations Strengthened SARS-CoV-2 Infectivity
- (2020) Jiahui Chen et al. JOURNAL OF MOLECULAR BIOLOGY
- Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
- (2020) Kui K. Chan et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SKEMPI 2.0: An updated benchmark of changes in protein-protein binding energy, kinetics and thermodynamics upon mutation
- (2018) Justina Jankauskaitė et al. BIOINFORMATICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started